4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

expected growth as well as a full year of contribution from both Verona’s Ohtuvayre and Merck’s Capvaxive. Captisol sales are expected to rise over 30% to $35 to $40 million, propelled by an ...

U.K. researchers at Nottingham Trent University, the University of Southampton and University Hospital Southampton and product development company Zelemiq Ltd. developed a wearable sensor that ...

The FDA approved ensifentrine (Ohtuvayre; Verona) for COPD in June. It is a phosphodiesterase-3 and phosphodiesterase-4 inhibitor indicated for maintenance treatment of COPD in adults.¹¹ Efficacy was ...

This impressive performance was largely driven by $10.1 million in milestone payments, attributed to the FDA approvals of Ohtuvayre and Capvaxive, as well as the conditional marketing approval of ...

The revenue was entirely generated from sales of Ohtuvayre, the company's sole marketed product. Following these results, H.C. Wainwright maintained a Buy rating on Verona Pharma shares and raised ...

The company's current product candidate and potential value creator is ensifentrine (commercially "Ohtuvayre"), an inhaled and dual inhibitor that acts as both a bronchodilator and an anti ...

Verona Pharma (NASDAQ: NASDAQ:VRNA) sustained a Buy rating and a $36.00 price target from H.C. Wainwright, following the announcement that its regional partner, Nuance Pharma, has completed patient ...